<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Journal of microbiology, epidemiology and immunobiology</journal-id><journal-title-group><journal-title xml:lang="en">Journal of microbiology, epidemiology and immunobiology</journal-title><trans-title-group xml:lang="ru"><trans-title>Журнал микробиологии, эпидемиологии и иммунобиологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0372-9311</issn><issn publication-format="electronic">2686-7613</issn><publisher><publisher-name xml:lang="en">Central Research Institute for Epidemiology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">13347</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">TARGET-DIRECTED SEARCH OF ANTI-VIRULENCE DRUGS</article-title><trans-title-group xml:lang="ru"><trans-title>МИШЕНЬ-НАПРАВЛЕННЫЙ ПОИСК АНТИВИРУ ЛЕНТНЫХ ЛЕКАРСТВЕННЫХ СРЕДСТВ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Zigangirova</surname><given-names>N. A</given-names></name><name xml:lang="ru"><surname>Зигангирова</surname><given-names>Н. А</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Fedina</surname><given-names>E. D</given-names></name><name xml:lang="ru"><surname>Федина</surname><given-names>Е. Д</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Zorina</surname><given-names>V. V</given-names></name><name xml:lang="ru"><surname>Зорина</surname><given-names>В. В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Bortsov</surname><given-names>P. A</given-names></name><name xml:lang="ru"><surname>Борцов</surname><given-names>П. А</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Tokarskaya</surname><given-names>E. A</given-names></name><name xml:lang="ru"><surname>Токарская</surname><given-names>Е. А</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Karyagina</surname><given-names>A. S</given-names></name><name xml:lang="ru"><surname>Карягина</surname><given-names>А. С</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Alekseevsky</surname><given-names>A. V</given-names></name><name xml:lang="ru"><surname>Алексеевский</surname><given-names>А. В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Krayushkin</surname><given-names>M. M</given-names></name><name xml:lang="ru"><surname>Краюшкин</surname><given-names>М. М</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Zayakin</surname><given-names>E. S</given-names></name><name xml:lang="ru"><surname>Заякин</surname><given-names>Е. С</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Yarovenko</surname><given-names>V. N</given-names></name><name xml:lang="ru"><surname>Яровенко</surname><given-names>В. Н</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Gintsburg</surname><given-names>A. L</given-names></name><name xml:lang="ru"><surname>Гинцбург</surname><given-names>А. Л</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Gamaleya Research Institute of Epidemiology and Microbiology</institution></aff><aff><institution xml:lang="ru">НИИ эпидемиологии и микробиологии им. Н.Ф.Гамалеи</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Zelinsky Institute of Organic Chemistry</institution></aff><aff><institution xml:lang="ru">Институт органической химии им. Н.Д.Зелинского</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Belozersky Institute of Physicochemical Biology at Lomonosov Moscow State University, Moscow, Russia</institution></aff><aff><institution xml:lang="ru">НИИ физико-химической биологии им. А.Н.Белозерского МГУ им. М.В.Ломоносова, Москва</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2009-08-15" publication-format="electronic"><day>15</day><month>08</month><year>2009</year></pub-date><volume>86</volume><issue>4</issue><issue-title xml:lang="en">NO4 (2009)</issue-title><issue-title xml:lang="ru">№4 (2009)</issue-title><fpage>71</fpage><lpage>77</lpage><history><date date-type="received" iso-8601-date="2023-06-09"><day>09</day><month>06</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2009, Zigangirova N.A., Fedina E.D., Zorina V.V., Bortsov P.A., Tokarskaya E.A., Karyagina A.S., Alekseevsky A.V., Krayushkin M.M., Zayakin E.S., Yarovenko V.N., Gintsburg A.L.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2009, Зигангирова Н.А., Федина Е.Д., Зорина В.В., Борцов П.А., Токарская Е.А., Карягина А.С., Алексеевский А.В., Краюшкин М.М., Заякин Е.С., Яровенко В.Н., Гинцбург А.Л.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder xml:lang="en">Zigangirova N.A., Fedina E.D., Zorina V.V., Bortsov P.A., Tokarskaya E.A., Karyagina A.S., Alekseevsky A.V., Krayushkin M.M., Zayakin E.S., Yarovenko V.N., Gintsburg A.L.</copyright-holder><copyright-holder xml:lang="ru">Зигангирова Н.А., Федина Е.Д., Зорина В.В., Борцов П.А., Токарская Е.А., Карягина А.С., Алексеевский А.В., Краюшкин М.М., Заякин Е.С., Яровенко В.Н., Гинцбург А.Л.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://microbiol.crie.ru/jour/article/view/13347">https://microbiol.crie.ru/jour/article/view/13347</self-uri><abstract xml:lang="en"><p>Modern medicine now encounters with problem of the absence of effective antibacterial drugs, which are able to render therapeutic effect on chronic form of infectious process. Thus, the actual objective is to develop essentially new generation of drugs, on the basis of which should lie identification of new bacterial targets playing key role in process of chronization of infection as well as selection of new physiologically active substances, which are able to render highly specific inhibitory effect on selected target. Solving of this objective is possible during realization of new approaches for search and design of new drugs and, first of all, during usage of bioinformatics methods, which enable to identify new biotargets, select most effective chemical compounds-inhibitors and optimize their pharmacological and pharmacokinetic properties. The most promising bacterial target is secretion systems of pathogenic microorganisms participating in realization of their virulent characteristics and playing major role in transition of infectious process in chronic phase. We performed synthesis of and screening for 80 compounds, which allowed to select a range of inhibitors rendering specific target-directed effect on type 3 secretion system of Chlamydia. Obtained data allow to further assess of biological and therapeutic activity of these compounds on developed models of infectious process in vivo .</p></abstract><trans-abstract xml:lang="ru"><p>Современная медицина на данный момент столкнулась с проблемой отсутствия эффективных антибактериальных препаратов, способных оказывать терапевтический эффект на хроническую форму инфекционного процесса. В связи с этим, актуальной задачей является создание принципиально нового поколения лекарственных средств, в основе которой лежит идентификация новых бактериальных мишеней, играющих ключевую роль в процессе хронизации инфекции, и выбор новых физиологически активных веществ, способных оказывать высоко специфичный ингибирующий эффект по отношению к выбранной мишени. Решение этой задачи возможно при реализации новых подходов к поиску и конструированию лекарственных препаратов, в первую очередь, при использовании биоинформационных методов, позволяющих идентифицировать новые биомишени, осуществить выбор наиболее эффективных химических соединений-ингибиторов и оптимизировать их фармацевтические и фармакокинетические свойства. Наиболее перспективной бактериальной мишенью являются системы секреции патогенных микроорганизмов, участвующие в реализации их вирулентных свойств и играющие ведущую роль в переходе инфекционного процесса в хроническую стадию. Нами проведен синтез и скрининг более 80 соединений, который позволил выбрать ряд ингибиторов, оказывающих специфический мишень-направленный эффект на систему секреции третьего типа Chlamydia. Полученные данные позволяют использовать данные соединения для дальнейшей оценки их биологической и терапевтической активности на разработанных моделях инфекционного процесса in vivo.</p></trans-abstract><kwd-group xml:lang="en"><kwd>Chlamydia</kwd><kwd>Brucella</kwd><kwd>chronic infection</kwd><kwd>secretion systems</kwd><kwd>secretion systems inhibitors</kwd><kwd>leader compounds</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>хроническая инфекция</kwd><kwd>системы секреции</kwd><kwd>ингибиторы системы секреции</kwd><kwd>лидерные соединения</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Зефирова О.Н., Зефиров Н. С. Медицинская химия. Методологические основы создания лекарственных препаратов. Вестн. Моск. ун-та. Сер. 2. Химия. 2000, 41 (2): 103-108.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Зефиров Н.С., Зефирова О.Н. Рациональный дизайн лекарственных средств. Химия и жизнь. 2004, 11: 6-9.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Прядко А. Курск на перемены. Фармацевт. вест. 2008, 22: 1-3.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Семенов Б.Ф. Концепция создания быстрой иммунологической защиты от патогенов. Журн. микробиол.2007, 4: 93-100.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Bailey L., Gylfe A., Sundin C. et al. Small molecule inhibitors of type III secretion in Yersinia block the Chlamydia pneumoniae infection cycle. FEBS Lett. 2007, 581 (4): 587-595.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Baron C., Coombes B. Targeting bacterial secretion systems: benefits of disarmament in the microcosm. Infect. Disord. Drug. Targets. 2007, 7 (1): 19-27.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Benson R.E., Gottlin E.B., Christensen D.J. et al. Intracellular expression of peptide fusions for demon- stration of protein essentiality in bacteria. Antimicrob. Agents. Chemother. 2003, 47 (9): 2875–2881.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Cegelski L., Marshall G.L., Eldridge G.R. et al. The biology and future prospects of antivirulence therapies. Nat. Rev. Microbiol. 2008, 6 (1): 17–27.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Clatworthy A.E., Pierson E., Hung D.T. Targeting virulence: a new paradigm for antimicrobial therapy. Nat. Chem. Biol. 2007, 3 (9): 541-548.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Clifton D.R., Fields K.A., Grieshaber S.S.et al. A chlamydial type III translocated protein is tyrosine-phosphorylated at the site of entry and associated with recruitment of actin. PNAS. 2004, 101 (27): 10166–10171.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Dahlgren M.K., Kauppi A.M., Olsson I.M. et al. Design, synthesis, and multivariate quantitative structure-activity relationship of salicylanilides-potent inhibitors of type III secretion in Yersinia. J. Med. Chem. 2007, 50 (24): 6177—6188.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Fan B.T., Lu H., Hu H. et al. Inhibition of apoptosis in Chlamydia-infected cells: blockade of mitochondrial cytochrome c release and caspase activation. J.Exp. Med. 1998, 187 (4):487–496.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Fisher S.F., Schwarz C., Vier J. et al. Characterization of antiapoptotic activities of Chlamydia pneumoniae in human cells. Infect.Immun. 2001, 69 (11):7121–7129.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Fischer S.F., Vier J., Kirschnek S. et al. Chlamydia inhibit host cell apoptosis by degradation of proapoptotic BH3-only proteins. J. Exp. Med. 2004, 200 (7): 905–916.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Galan JE, Collmer A. Type III Secretion machines: bacterial devices for protein delivery into host cells. Science. 1999, 284(5418): 1322-1328.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Höppner C., Liu Z., Domke N. et al. VirB1 orthologs from Brucella suis and pKM101 complement defects of the lytic transglycosylase required for efficient type IV secretion from Agrobacterium tumefaciens. J. Bacteriol. 2004, 186 (5): 1415-1422.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Hueck C.J. Type III protein secretion systems in bacterial pathogens of animals and plants. Microbiol. Mol. Biol. Rev. 1998, 62 (2): 379-433.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>King F. D., Chem R. S. Medicinal chemistry: principles and practice. Cambridge, 1994.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Muschiol S., Bailey L., Gylfe A. et al. A small-molecule inhibitor of type III secretion inhibits different stages of the infectious cycle of Chlamydia trachomatis. PNAS. 2006, 103 (39): 14566–14571.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Nabipour I., Vahdat K., Jafari S.M. et al. The association of metabolic syndrome and Chlamydia pneumoniae, Helicobacter pylori, cytomegalovirus, and herpes simplex virus type 1: the persian gulf healthy heart study. Cardiovasc. Diabetol. 2006, 5: 1-6.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Niels H., Bjarne H., Jens J. Occurrence and pathogenic potential of Bacillus cereus group bacteria in a sandy loam. Antonie van Leeuwenhoek. 2006, 89 (2—3): 239-249.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Neumann F. Chlamydia pneumoniae-Atherosclerosis Link. Circulation. 2002, 106 (19): 2414-2426.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Peters J.M., Wilson D.P., Myers G. et al. Type III secretion à la Chlamydia. Trends Microbiol. 2007,15 (6): 241-251.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Rad R., Prinz C., Schmid R. Helicobacter pylori and prognosis of gastric carcinoma. Lancet Oncol. 2006, 7 (5): 364—365.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Ramensky V., Sobol A., Zaitseva N. et al. A novel approach to local similarity of protein binding sites substantially improves computational drug design results. Proteins. 2007, 69: 349–357.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Shaw E.I., Dooley С.A., Fischer E.R. et al. Three temporal classes of gene expression during the Chlamydia trachomatis developmental cycle. Mol. Microbiol. 2000, 37 (4): 913–925.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Verbeke P., Welter-Stahl L., Ying S. et al. Recruitment of BAD by the Chlamydia trachomatis vacuole correlates with host-cell survival. PLoS Pathog. 2006, 2 (5): 0408-0417.</mixed-citation></ref></ref-list></back></article>
